Aura Biosciences (AURA) Gains from Investment Securities (2021 - 2022)
Aura Biosciences' (AURA) quarterly Gains from Investment Securities came in at -$61000.0 in Q2 2022, down 2133.33% YoY from $3000.0 in Q2 2021, and down 238.64% on a QoQ basis from $44000.0 in Q1 2022.
Powered by 
Analysis
Aura Biosciences (AURA) Gains from Investment Securities (2021 - 2022) Analysis & Trends
Aura Biosciences (AURA) has 2 years of Gains from Investment Securities data on file, last reported at -$61000.0 in Q2 2022.
- Quarterly Gains from Investment Securities fell 2133.33% year-over-year to -$61000.0 in Q2 2022, while the trailing twelve-month figure through Jun 2022 was -$5000.0 (changed N/A YoY) and the FY2021 annual result came in at $11000.0, up 466.67% from the prior year.
- Gains from Investment Securities eased to -$61000.0 in Q2 2022, from $44000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $44000.0 in Q1 2022 to a low of -$61000.0 in Q2 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Aura Biosciences | 717.17 Mn | 649.33 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2022 | -61,000.00 |
| Mar 31, 2022 | 44,000.00 |
| Dec 31, 2021 | 12,000.00 |
| Jun 30, 2021 | 3,000.00 |
| Mar 31, 2021 | -4,000.00 |